By Peter A. McCullough, MD, MPH
One of the fundamental aspects ofTamura TJ, Choudhary MC, Deo R, et al. Emerging SARS-CoV-2 Resistance After Antiviral Treatment. JAMA Netw Open. 2024;7(9):e2435431. doi:10.1001/jamanetworkopen.2024.35431
Tamura et al from the POSITIVES study team has found that 11% of those treated with paxlovid have become resistant to the antiviral nirmatrelvir. Resistance was more common in the immunocompromised and with paxlovid rebound. With continued use this proportion will undoubtedly grow larger. No such resistance has been described with hydroxychloroquine or ivermectin used in the McCullough Protocol.
Please subscribe to Courageous Discourse as a paying ($5 monthly) or founder member so we can continue to bring you the truth.
Peter A. McCullough, MD, MPH
President, McCullough Foundation
www.mcculloughfnd.org
Tamura TJ, Choudhary MC, Deo R, et al. Emerging SARS-CoV-2 Resistance After Antiviral Treatment. JAMA Netw Open. 2024;7(9):e2435431. doi:10.1001/jamanetworkopen.2024.35431
Click this link for the original source of this article.
Author: Peter A. McCullough, MD, MPH
This content is courtesy of, and owned and copyrighted by, https://petermcculloughmd.substack.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.
